Ajooni Biotech Ltd

Ajooni Biotech Ltd recorded a modest weekly gain of 1.04%, closing at Rs.3.89 on 30 January 2026, despite the broader Sensex advancing 1.62% over the same period. The stock’s performance was marked by volatility amid a backdrop of strong quarterly financial results and mixed investor sentiment, resulting in a week of fluctuating price movements and volume spikes.

Ajooni Biotech Ltd's latest results show strong revenue growth of 72.64% year-on-year, reaching ₹58.75 crores, and a net profit increase of 126.03%. However, profitability margins remain a concern, with low return on equity and capital employed, indicating ongoing operational challenges.

On 24-Dec, Ajooni Biotech Ltd’s stock price rose by 1.82% to ₹4.47, outperforming its sector and the broader market despite a challenging long-term performance record and weak fundamental indicators.

Ajooni Biotech has shown significant growth in net sales and profit, with net sales increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, and profit after tax rising from 0.41 crore to 3.37 crore. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash management.

As of 19-Nov, Ajooni Biotech Ltd's stock price is Rs. 4.67, down 5.47%, and has reached a 52-week low of Rs. 4.16. The stock is underperforming significantly compared to the Sensex, with a year-to-date decline of 39.90% and decreasing investor participation.

Ajooni Biotech has shown significant growth in net sales and profitability, with net sales increasing from 39.72 Cr in Mar'19 to 114.69 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 3.37 Cr in the same period. However, the company faces challenges in cash flow management, experiencing a net cash outflow of 10.00 Cr in Mar'25.

Ajooni Biotech has shown significant growth in net sales and profitability from March 2021 to March 2025, with net sales increasing from 51.04 crore to 114.69 crore and profit after tax rising from 0.37 crore to 3.37 crore, despite experiencing negative cash flow in March 2025. Total assets and liabilities have also expanded substantially during this period.

Ajooni Biotech has shown significant growth in net sales and profitability, with net sales increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, and profit after tax rising from 0.41 crore to 3.37 crore during the same period. However, the company faced negative cash flow from operating activities of -17.00 crore in March 2025.

Ajooni Biotech has shown significant growth in net sales, increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, with profit after tax rising from 0.41 crore to 3.37 crore during the same period, despite fluctuations in cash flow. Total assets and liabilities also grew substantially, reflecting the company's overall financial expansion.

Ajooni Biotech has shown significant growth in net sales and profitability from 2021 to 2025, with net sales increasing from 51.04 Cr to 114.69 Cr and profit after tax rising from 0.35 Cr to 3.37 Cr. However, cash flow from operating activities turned negative in 2025, contrasting with a positive cash flow in 2024.

As of 12-Sep, Ajooni Biotech Ltd's stock price is Rs 5.15, down 0.19%, and has significantly underperformed the market, with a 50.19% decline over the past year. Despite positive quarterly results, the stock's weak fundamentals and poor performance compared to the Sensex highlight ongoing challenges in attracting investor confidence.